People with heart failure, especially weak pumping, tend to have higher levels of PCSK9 in their blood, and the higher it is, the worse their outlook tends to be.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether baseline PCSK9 levels predict future heart failure hospitalization or death.
A prospective cohort study of 3,000 patients with cardiovascular disease, measuring baseline PCSK9 and following for 5 years to assess heart failure hospitalization, cardiovascular death, and changes in ejection fraction, adjusting for LDL-C and natriuretic peptides.
The prevalence of high PCSK9 in heart failure patients vs controls.
A cross-sectional study comparing PCSK9 levels in 500 HFrEF patients, 500 HFpEF patients, and 500 healthy controls, matched for age and sex.
Whether PCSK9 levels differ between heart failure patients and healthy individuals.
A case-control study of 400 heart failure patients and 400 controls, measuring PCSK9 and adjusting for comorbidities and medications.
Whether lowering PCSK9 improves outcomes in heart failure patients.
A double-blind RCT of 5,000 HFrEF patients randomized to alirocumab vs placebo, measuring changes in NT-proBNP, 6-minute walk test, and hospitalization over 18 months.
Synthesis of current evidence on PCSK9 as a heart failure biomarker.
A narrative review summarizing clinical studies on PCSK9 levels in heart failure patients.